


THE IMPORTANCE OF HEMATOLOGICAL PARAMETERS IN HEART FAILURE PROGNOSIS - EVIDENCE FROM THE REFERENCE STUDY

Mário Barbosa<sup>1</sup>, Andreia Matos<sup>2,3</sup>, Manuel Bicho<sup>2,3</sup>, Luiz Menezes Falcão<sup>3,4</sup>

<sup>1</sup> Department of Internal Medicine, Hospital Lusíadas Lisboa, Lisbon, Portugal; <sup>2</sup> Genetics Laboratory and Environmental Health Institute-ISAMB, Faculty of Medicine, University of Lisbon, Portugal; <sup>3</sup> Instituto de Investigação Científica Bento da Rocha Cabral; <sup>4</sup> Faculty of Medicine, University of Lisbon; <sup>5</sup> Department of Internal Medicine, Santa Maria Hospital, Lisbon, Portugal.



**BACKGROUND:** In patients with heart failure (HF), anemia and iron deficiency are predictors of poor long-term outcome.

**OBJECTIVE:** The purpose of this study was to examine the association of anemia, iron deficiency, and related hematological parameters with early (defined as the period of 90 days post-discharge) rehospitalization due to HF and all-cause mortality, and long-term all-cause mortality in HF patients.

**METHODS:** Anemia, iron deficiency, red cell distribution width (RDW) and erythropoietin (EPO) were assessed in patients hospitalized with acute decompensated heart failure in class III or IV of New York Heart Association (NYHA) to an Internal Medicine ward. Comparison between patients with and without each of the events was performed for all variables using t test or Wilcoxon Rank test as applicable. Categorical variables were summarized by relative and absolute frequencies, and compared using chi-squared test or Fisher’s Exact test as applicable. Univariate Cox proportional hazard model was used to assess the relationship between variables and outcomes.

RESULTS

Table 1 – General baseline characteristics

| Characteristics                               | Patients (n=65)    |
|-----------------------------------------------|--------------------|
| Age, mean (SD)                                | 79.2 ± 10.8        |
| Female Gender, n (%)                          | 37 (56.9)          |
| Hypertension, n (%)                           | 58 (89.2)          |
| Type 2 Diabetes, n (%)                        | 25 (38.5)          |
| Dyslipidemia, n (%)                           | 41 (63.1)          |
| Obesity, n (%)                                | 17 (26.2)          |
| Atrial Fibrillation, n (%)                    | 28 (43.1)          |
| Family History of CVD, n (%)                  | 31 (47.7)          |
| Tabagism, n (%)                               | 21 (32.3)          |
| Chronic Kidney Disease, n (%)                 | 34 (52.3)          |
| GFR (Baseline), median                        | 57.8 (43.8 - 82.2) |
| GFR (Admission), median                       | 47.9 (33.2 - 68.1) |
| Previous Acute Myocardial Infarction, n (%)   | 27 (41.5)          |
| Hypertensive Cardiomyopathy, n (%)            | 44 (67.7)          |
| Ischemic Cardiomyopathy, n (%)                | 22 (33.8)          |
| Valvular Cardiomyopathy, n (%)                | 56 (86.2)          |
| LVEF, mean (SD)                               | 50.38 ± 19.07      |
| NYHA class III, n (%)                         | 43 (66.2)          |
| ACE Inhibitor, n (%)                          | 43 (66.2)          |
| Beta Blocker, n (%)                           | 38 (58.5)          |
| Mineralocorticoid Receptor Antagonists, n (%) | 19 (29.2)          |
| Angiotensin II Receptor Blocker, n (%)        | 11 (16.9)          |
| Loop Diuretic, n (%)                          | 54 (83.1)          |
| Digoxin, n (%)                                | 8 (12.3)           |

Table 2 – Hematological parameters baseline characteristics

| Characteristics                                  | Patients (n=65)      |
|--------------------------------------------------|----------------------|
| Hemoglobin, mean (SD)                            | 11.7 ± 1.9           |
| Red Blood Cell Distribution Width, median        | 15.0 (13.8 - 16.2)   |
| Transferrin Saturation, median                   | 14.0 (10 - 21)       |
| Total Iron-Binding Capacity, mean (SD)           | 281.5 ± 76.1         |
| Serum Iron, median                               | 40.1 (27.6 - 60.1)   |
| Serum Ferritin, median                           | 149.1 (52.3 - 350.9) |
| Iron Deficiency, n (%)                           | 30 (46.2)            |
| Anemia, n (%)                                    | 38 (58.5)            |
| Anemia with Iron Deficiency, n (%)               | 17 (26.2)            |
| Absolute Iron Deficiency, n (%)                  | 20 (30.1)            |
| Functional Iron Deficiency, n (%)                | 10 (15.4)            |
| Anemia without Iron Deficiency, n (%)            | 15 (23.0)            |
| Iron Deficiency without Anemia, n (%)            | 13 (20.0)            |
| Absolute Iron Deficiency without Anemia, n (%)   | 6 (9.2)              |
| Functional Iron Deficiency without Anemia, n (%) | 7 (10.8)             |


Values are median (IQR), n (%), or mean±SD.  
IQR: interquartile range and minimum/maximum, SD: standard deviation.

N=65 HF patients  
Mean age: 79.2 (SD 10.8)

Median follow-up : 13.7 months  
[Q1: 6.7 to Q3: 18.9]


Values are median (IQR), n (%), or mean±SD.  
IQR: interquartile range and minimum/maximum, SD: standard deviation, CVD: cardiovascular disease, GFR: glomerular filtration rate, ACE: Angiotensin-Converting-Enzyme.

Risk for early rehospitalization



Increased risk for early mortality

Forest Plot of Hazard Ratios by Patient Subgroups



Increased risk for long-term mortality

Forest Plot of Hazard Ratios by Patient Subgroups




Figure 1- Baseline comparison of subjects by early rehospitalization status: Anemia





Figure 3 - Short-term mortality - Kaplan Meier: Serum ferritin <100 ng/mL



CONCLUSION:

- Anemia, iron deficiency, RDW and EPO were associated with early rehospitalization, early mortality, and long-term mortality.
- Our findings may provide insight into HF prognosis and may raise the interest in some neglected hematological parameters.
- The recognition and treatment of risk factors that influence HF outcome, beyond HF specific therapy, may further contribute to ameliorate HF prognosis.